Want to see WVE full AI Analyst Report?
WVE Stock Chart & Stats
$5.81
$0.12(2.07%)
At close: 4:00 PM EDT
$5.81
$0.12(2.07%)
Day’s Range― - ―
52-Week Range$5.01 - $21.73
Previous CloseN/A
Volume649.21K
Average Volume (3M)2.75M
Market Cap
$1.00B
Enterprise Value$738.28
Total Cash (Recent Filing)$490.60M
Total Debt (Recent Filing)$43.59M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Nov 05, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding197,048,170
10 Day Avg. Volume1,967,726
30 Day Avg. Volume2,749,384
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.45
Price to Sales (P/S)67.10
P/FCF Ratio-15.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.17Price Target Upside264.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.11
Revenue Forecast (FY)$52.83M
Bulls Say, Bears Say
Bulls Say
Balance Sheet / RunwayA cash balance of $490.6M and management’s stated runway into Q3 2028 materially reduces near-term financing pressure for a clinical-stage biotech. This durable liquidity cushion allows the company to fund multi-year clinical programs and regulatory interactions without immediate dilutive raises, preserving strategic optionality for partnerships or registrational path execution over the next 2–6 months and beyond.
Regulatory EngagementSecuring an FDA meeting to discuss a potential accelerated approval pathway for WVE-006 is a structural positive: it signals constructive regulator engagement and could materially de-risk the program’s path to market. For a therapy addressing a defined PiZZ AATD population, an accelerated pathway would shorten commercialization timelines and strengthen the program’s strategic and revenue prospects if clinical data align with regulatory expectations.
Platform & Clinical MomentumRobust Phase I signal for WVE-007 (sustained Activin E reductions, favorable body composition effects) combined with initiation of a multidose Phase IIa demonstrates platform translational potential. Sustained clinical progress across multiple programs (WVE-007, WVE-006, WVE-008) and planned combination/post-incretin studies support the company’s SpiNA chemistry and RNA editing differentiation, underpinning medium-term commercial opportunity and partner interest.
Bears Say
High Cash BurnPersistent negative operating and free cash flow (TTM ~-189.9M and -191.5M) means the company is consuming cash to fund R&D and operations rather than generating it. Over the medium term this raises funding risk and increases the likelihood of financing events or milestone-dependent liquidity, which can dilute shareholders and constrain the firm’s ability to accelerate multiple programs simultaneously.
Sustained LossesLarge, persistent operating losses (TTM EBIT and net loss exceeding $200M) despite very high gross margins indicate the business remains in an intensive investment phase without operating leverage. This structural unprofitability reduces return metrics, pressures equity stability, and means value realization hinges on future regulatory success and commercialization rather than current operating profitability.
Revenue & Collaboration VolatilitySharp decline in collaboration revenue (Q2 down ~73.6% YoY) highlights reliance on uneven partner payments and milestone timing. This structural revenue volatility makes near-term cash flow unpredictable, increases dependence on milestone-triggered receipts and external financing, and weakens the company’s ability to demonstrate stable commercial traction independent of partner arrangements.
Wave Life Sciences News
WVE FAQ
What was Wave Life Sciences’s price range in the past 12 months?
Wave Life Sciences lowest stock price was $5.01 and its highest was $21.73 in the past 12 months.
What is Wave Life Sciences’s market cap?
Wave Life Sciences’s market cap is $1.00B.
When is Wave Life Sciences’s upcoming earnings report date?
Wave Life Sciences’s upcoming earnings report date is Nov 05, 2026 which is in 78 days.
How were Wave Life Sciences’s earnings last quarter?
Wave Life Sciences released its earnings results on Jul 30, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.04.
Is Wave Life Sciences overvalued?
According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued.
Does Wave Life Sciences pay dividends?
Wave Life Sciences does not currently pay dividends.
What is Wave Life Sciences’s EPS estimate?
Wave Life Sciences’s EPS estimate is -0.32.
How many shares outstanding does Wave Life Sciences have?
Wave Life Sciences has 197,048,170 shares outstanding.
What happened to Wave Life Sciences’s price movement after its last earnings report?
Wave Life Sciences reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went down -0.861%.
Which hedge fund is a major shareholder of Wave Life Sciences?
Currently, no hedge funds are holding shares in WVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wave Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.17 (264.31% Upside)
$21.17 (264.31% Upside)
Blogger Sentiment
Neutral
WVE Sentiment 50%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 9.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
121.24%
Trailing 12-Months
Company Description
Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
WVE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical momentum across the lead programs (WVE-007, WVE-006, WVE-008) with compelling early human and preclinical data, regulatory engagement (FDA meeting for 006), and a solid cash balance supporting operations into Q3 2028. Offsetting these positives are a pronounced YoY revenue decline (-73.6%), rising R&D and G&A spend driving a larger net loss (+37.4% YoY), dependency on future milestone payments not included in runway calculations, and timing/regulatory uncertainties (including partnership-driven strategy for DMD). On balance, the clinical and platform progress and runway position are dominant positives despite near-term financial headwinds and program/timing uncertainties.View all WVE earnings summariesWVE Stock 12 Month Forecast
Average Price Target
$21.17
▲(264.31% Upside)
Technical Analysis
Precigen
―
Stoke Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Rapport Therapeutics, Inc.
―
Ownership Overview
28.49% Insiders
14.24% Mutual Funds
0.22% Other Institutional Investors
48.45% Public Companies and Individual Investors